analyzers,assays,clinics,diagnostic,end user,hospitals,kits,laboratory,pcr
The global CT/NG testing market is projected to reach USD 2.7 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 8.6% during the forecast period. Increasing prevalence of CT/NG infections, steady investments and funds in CT/NG and rising attempts in awareness for CT/NG diagnosis are factors driving the growth of this market. However high prices of CT/NG testing instruments and kits along with scarcity in technicians is likely to hamper the growth of CT/NG testing market.
図表リスト1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 25 1.3 STUDY SCOPE 25 1.3.1 MARKETS COVERED 25 1.3.2 GEOGRAPHIC SCOPE 26 1.3.3 YEARS CONSIDERED 26 1.4 CURRENCY CONSIDERED 27 1.5 LIMITATIONS 27 1.6 STAKEHOLDERS 27 1.7 SUMMARY OF CHANGES 28 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 2.2 RESEARCH APPROACH 29 FIGURE 1 CT/NG TESTING MARKET: RESEARCH DESIGN 29 2.2.1 SECONDARY DATA 30 2.2.1.1 Key data from secondary sources 30 2.2.2 PRIMARY DATA 31 2.2.2.1 Primary sources 32 2.2.2.2 Key data from primary sources 33 2.2.2.3 Key industry insights 34 2.2.2.4 Breakdown of primary interviews 34 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 34 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35 2.3 MARKET SIZE ESTIMATION 35 2.3.1 BOTTOM-UP APPROACH 36 2.3.1.1 Approach 1: Company revenue estimation approach 36 FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36 2.3.1.2 Approach 2: Presentations of companies and primary interviews 36 2.3.1.3 Growth forecast 37 2.3.1.4 CAGR projections 37 FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37 2.3.2 TOP-DOWN APPROACH 37 FIGURE 6 CT/NG TESTING MARKET: TOP-DOWN APPROACH 38 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39 FIGURE 7 DATA TRIANGULATION METHODOLOGY 39 2.5 MARKET SHARE ANALYSIS 40 2.6 STUDY ASSUMPTIONS 40 2.7 GROWTH RATE ASSUMPTIONS 40 2.8 RISK ASSESSMENT 41 2.8.1 CT/NG TESTING MARKET: RISK ASSESSMENT 41 2.9 RECESSION IMPACT 41 3 EXECUTIVE SUMMARY 44 FIGURE 8 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 44 FIGURE 9 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 (USD MILLION) 45 FIGURE 10 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 45 FIGURE 11 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46 FIGURE 12 CT/NG TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 46 4 PREMIUM INSIGHTS 48 4.1 CT/NG TESTING MARKET OVERVIEW 48 FIGURE 13 INCREASING PREVALENCE OF CT/NG INFECTIONS TO DRIVE MARKET 48 4.2 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 48 FIGURE 14 ASSAYS AND KITS SEGMENT TO DOMINATE CT/NG TESTING MARKET IN 2028 48 4.3 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 49 FIGURE 15 LABORATORY TESTING SEGMENT TO DOMINATE MARKET IN 2028 49 4.4 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 49 FIGURE 16 PCR SEGMENT TO DOMINATE CT/NG TESTING MARKET DURING STUDY PERIOD 49 4.5 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 50 FIGURE 17 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET IN 2028 50 4.6 CT/NG TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 50 FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN CT/NG TESTING MARKET DURING FORECAST PERIOD 50 5 MARKET OVERVIEW 51 5.1 INTRODUCTION 51 5.2 MARKET DYNAMICS 51 FIGURE 19 CT/NG TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 5.2.1 DRIVERS 52 5.2.1.1 Increasing prevalence of CT/NG infections 52 5.2.1.2 Increasing investments and initiatives in CT/NG 52 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies 53 5.2.2 RESTRAINTS 54 5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies 54 5.2.2.2 High cost of instruments and lack of budget for small laboratories and physicians’ offices 54 5.2.3 OPPORTUNITIES 55 5.2.3.1 Growth opportunities in emerging economies 55 5.2.4 CHALLENGES 55 5.2.4.1 Changing regulatory landscape in European Union and US 55 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians 56 5.3 PRICING ANALYSIS 56 TABLE 1 AVERAGE SELLING PRICE OF CT/NG TESTING PRODUCTS (2023) 56 5.4 PATENT ANALYSIS 57 FIGURE 20 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022) 57 5.4.1 LIST OF KEY PATENTS 58 5.5 VALUE CHAIN ANALYSIS 59 FIGURE 21 VALUE CHAIN ANALYSIS OF CT/NG TESTING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 60 5.6 SUPPLY CHAIN ANALYSIS 60 FIGURE 22 CT/NG TESTING MARKET: SUPPLY CHAIN ANALYSIS 61 5.7 ECOSYSTEM MARKET MAP 61 FIGURE 23 CT/NG TESTING MARKET: ECOSYSTEM MARKET MAP 62 5.7.1 CT/NG TESTING MARKET: ROLE IN ECOSYSTEM 62 5.8 PORTER’S FIVE FORCES ANALYSIS 63 TABLE 2 CT/NG TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 63 5.8.1 THREAT OF NEW ENTRANTS 63 5.8.2 THREAT OF SUBSTITUTES 63 5.8.3 BARGAINING POWER OF BUYERS 63 5.8.4 BARGAINING POWER OF SUPPLIERS 64 5.8.5 INTENSITY OF COMPETITIVE RIVALRY 64 5.9 REGULATORY ANALYSIS 64 TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64 TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 5.9.1 NORTH AMERICA 66 5.9.1.1 US 66 5.9.1.2 Canada 66 5.9.2 EUROPE 66 TABLE 7 EUROPE: CLASSIFICATION OF DEVICES 66 5.9.3 ASIA PACIFIC 67 5.9.3.1 China 67 5.9.3.2 Japan 67 TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 67 5.9.3.3 India 68 5.9.4 LATIN AMERICA 68 5.9.4.1 Brazil 68 5.9.4.2 Mexico 68 5.9.5 MIDDLE EAST 68 5.9.6 AFRICA 69 5.10 TRADE ANALYSIS 69 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 69 TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 69 TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 69 5.11 PESTLE ANALYSIS 70 5.12 TECHNOLOGY ANALYSIS 71 5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 71 TABLE 11 CT/NG TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 71 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73 5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR CT/NG TESTING PRODUCT MANUFACTURERS 73 5.14.2 REVENUE SHIFT IN CT/NG TESTING MARKET 73 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 73 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 73 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CT/NG TESTING PRODUCTS 73 TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CT/NG TESTING PRODUCTS 74 5.15.2 BUYING CRITERIA 74 FIGURE 25 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS 74 TABLE 13 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS 74 6 CT/NG TESTING MARKET, BY PRODUCT 75 6.1 INTRODUCTION 76 TABLE 14 CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 76 6.2 ASSAYS AND KITS 76 6.2.1 RECURRENT REQUIREMENT AND PURCHASE OF ASSAYS AND KITS TO DRIVE GROWTH 76 TABLE 15 KEY ASSAYS AND KITS OFFERED BY MARKET PLAYERS 77 TABLE 16 CT/NG TESTING MARKET FOR ASSAYS AND KITS, BY REGION, 2021–2028 (USD MILLION) 77 6.3 INSTRUMENTS/ANALYZERS 77 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST GROWTH 77 TABLE 17 KEY INSTRUMENTS/ANALYZERS OFFERED BY MARKET PLAYERS 78 TABLE 18 CT/NG TESTING MARKET FOR INSTRUMENTS/ANALYZERS, BY REGION, 2021–2028 (USD MILLION) 78 7 CT/NG TESTING MARKET, BY TESTING TYPE 79 7.1 INTRODUCTION 80 TABLE 19 CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 80 7.2 LABORATORY TESTING 80 7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASING FOCUS ON EARLY DISEASE DETECTION TO DRIVE GROWTH 80 TABLE 20 CT/NG TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2021–2028 (USD MILLION) 81 7.3 POINT-OF-CARE TESTING 81 7.3.1 FASTER TURNAROUND TIME TO DRIVE GROWTH 81 TABLE 21 CT/NG TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2021–2028 (USD MILLION) 82 8 CT/NG TESTING MARKET, BY TECHNOLOGY 83 8.1 INTRODUCTION 84 TABLE 22 CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 84 8.2 PCR 84 8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS TO DRIVE GROWTH 84 TABLE 23 CT/NG TESTING MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION) 85 8.3 INAAT 85 8.3.1 COST-BENEFITS OF INAAT TO DRIVE GROWTH 85 TABLE 24 CT/NG TESTING MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION) 86 8.4 IMMUNODIAGNOSTICS 86 8.4.1 RISING PREVALENCE OF CT/NG AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE GROWTH 86 TABLE 25 CT/NG TESTING MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 87 8.5 OTHER TECHNOLOGIES 87 TABLE 26 CT/NG TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 88 9 CT/NG TESTING MARKET, BY END USER 89 9.1 INTRODUCTION 90 TABLE 27 CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 90 9.2 DIAGNOSTIC LABORATORIES 90 9.2.1 AVAILABILITY OF WIDE RANGE OF TEST PANELS FOR DISEASE TESTING TO SUPPORT GROWTH 90 TABLE 28 CT/NG TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 91 9.3 HOSPITALS AND CLINICS 91 9.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE GROWTH 91 TABLE 29 CT/NG TESTING MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 92 9.4 OTHER END USERS 92 TABLE 30 CT/NG TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 93 10 CT/NG TESTING MARKET, BY REGION 94 10.1 INTRODUCTION 95 TABLE 31 CT/NG TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 95 10.2 NORTH AMERICA 95 FIGURE 26 NORTH AMERICA: CT/NG TESTING MARKET SNAPSHOT 96 TABLE 32 NORTH AMERICA: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97 TABLE 33 NORTH AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 97 TABLE 34 NORTH AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 97 TABLE 35 NORTH AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 98 TABLE 36 NORTH AMERICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 98 10.2.1 RECESSION IMPACT: NORTH AMERICA 98 10.2.2 US 99 10.2.2.1 Growing prevalence of infectious diseases to drive market 99 TABLE 37 US: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99 TABLE 38 US: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 99 TABLE 39 US: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 100 TABLE 40 US: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 100 10.2.3 CANADA 100 10.2.3.1 Rising government initiatives to propel market growth in coming years 100 TABLE 41 CANADA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101 TABLE 42 CANADA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 101 TABLE 43 CANADA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 101 TABLE 44 CANADA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 102 10.3 EUROPE 102 TABLE 45 EUROPE: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103 TABLE 46 EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103 TABLE 47 EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 103 TABLE 48 EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 104 TABLE 49 EUROPE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 104 10.3.1 RECESSION IMPACT: EUROPE 104 10.3.2 GERMANY 105 10.3.2.1 Increasing healthcare expenditure to drive market growth 105 TABLE 50 GERMANY: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 105 TABLE 51 GERMANY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 105 TABLE 52 GERMANY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 106 TABLE 53 GERMANY: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 106 10.3.3 UK 106 10.3.3.1 Growing number of accredited diagnostic laboratories to propel market growth 106 TABLE 54 UK: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 107 TABLE 55 UK: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 107 TABLE 56 UK: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 107 TABLE 57 UK: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 108 10.3.4 FRANCE 108 10.3.4.1 Rising R&D expenditure in France to drive market growth 108 TABLE 58 FRANCE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108 TABLE 59 FRANCE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 109 TABLE 60 FRANCE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 109 TABLE 61 FRANCE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 109 10.3.5 ITALY 110 10.3.5.1 Adoption of advanced diagnostic technologies to favor growth 110 TABLE 62 ITALY: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110 TABLE 63 ITALY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 110 TABLE 64 ITALY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 111 TABLE 65 ITALY: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 111 10.3.6 SPAIN 111 10.3.6.1 Growing demand for diagnostic testing in Spain to favor market growth 111 TABLE 66 SPAIN: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 112 TABLE 67 SPAIN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 112 TABLE 68 SPAIN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 112 TABLE 69 SPAIN: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 113 10.3.7 REST OF EUROPE 113 TABLE 70 REST OF EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 113 TABLE 71 REST OF EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 114 TABLE 72 REST OF EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114 TABLE 73 REST OF EUROPE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 114 10.4 ASIA PACIFIC 115 FIGURE 27 ASIA PACIFIC: CT/NG TESTING MARKET SNAPSHOT 116 TABLE 74 ASIA PACIFIC: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117 TABLE 75 ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 117 TABLE 76 ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 117 TABLE 77 ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118 TABLE 78 ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 118 10.4.1 RECESSION IMPACT: ASIA PACIFIC 118 10.4.2 CHINA 119 10.4.2.1 Growing public access to modern healthcare to drive market growth 119 TABLE 79 CHINA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119 TABLE 80 CHINA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 120 TABLE 81 CHINA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120 TABLE 82 CHINA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 120 10.4.3 JAPAN 121 10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan 121 TABLE 83 JAPAN: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121 TABLE 84 JAPAN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 122 TABLE 85 JAPAN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122 TABLE 86 JAPAN: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 122 10.4.4 INDIA 123 10.4.4.1 Increasing private and public investments in country’s healthcare system to drive market growth 123 TABLE 87 INDIA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123 TABLE 88 INDIA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 124 TABLE 89 INDIA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124 TABLE 90 INDIA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 124 10.4.5 REST OF ASIA PACIFIC 125 TABLE 91 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125 TABLE 92 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 125 TABLE 93 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126 TABLE 94 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 126 10.5 LATIN AMERICA 126 10.5.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE GROWTH OF CT/NG TESTING MARKET IN LATIN AMERICA 126 TABLE 95 LATIN AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127 TABLE 96 LATIN AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 127 TABLE 97 LATIN AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128 TABLE 98 LATIN AMERICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 128 10.5.2 RECESSION IMPACT: LATIN AMERICA 128 10.6 MIDDLE EAST & AFRICA 129 10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH 129 TABLE 99 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129 TABLE 100 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 130 TABLE 101 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130 TABLE 102 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 130 10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA 131 11 COMPETITIVE LANDSCAPE 132 11.1 OVERVIEW 132 11.2 STRATEGIES OF KEY PLAYERS 132 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CT/NG TESTING MARKET 132 TABLE 103 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CT/NG TESTING PRODUCTS MANUFACTURING COMPANIES 132 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 134 FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CT/NG TESTING MARKET 134 11.4 MARKET SHARE ANALYSIS 134 11.4.1 CT/NG TESTING MARKET 134 FIGURE 29 CT/NG TESTING MARKET SHARE, BY KEY PLAYER (2022) 135 TABLE 104 CT/NG TESTING MARKET: DEGREE OF COMPETITION 135 11.5 COMPANY EVALUATION MATRIX, 2022 136 11.5.1 STARS 136 11.5.2 EMERGING LEADERS 136 11.5.3 PERVASIVE PLAYERS 137 11.5.4 PARTICIPANTS 137 FIGURE 30 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX, 2022 137 11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 138 11.6.1 PROGRESSIVE COMPANIES 138 11.6.2 STARTING BLOCKS 138 11.6.3 RESPONSIVE COMPANIES 138 11.6.4 DYNAMIC COMPANIES 138 FIGURE 31 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 139 11.7 COMPETITIVE BENCHMARKING 140 11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 140 FIGURE 32 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS 140 TABLE 105 CT/NG TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 140 TABLE 106 PRODUCT FOOTPRINT OF COMPANIES 141 TABLE 107 REGIONAL FOOTPRINT OF COMPANIES 141 TABLE 108 CT/NG TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES 141 11.8 COMPETITIVE SCENARIO 142 11.8.1 PRODUCT LAUNCHES 142 TABLE 109 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 142 11.8.2 DEALS 142 TABLE 110 KEY DEALS 142 12 COMPANY PROFILES 143 12.1 KEY PLAYERS 143 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 12.1.1 F. HOFFMANN-LA ROCHE LTD 143 TABLE 111 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 143 FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 144 12.1.2 HOLOGIC, INC. 147 TABLE 112 HOLOGIC, INC.: BUSINESS OVERVIEW 147 FIGURE 34 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 148 12.1.3 THERMO FISHER SCIENTIFIC, INC. 150 TABLE 113 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 150 FIGURE 35 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 151 12.1.4 ABBOTT LABORATORIES 153 TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW 153 FIGURE 36 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 154 12.1.5 PERKINELMER, INC. 156 TABLE 115 PERKINELMER, INC.: BUSINESS OVERVIEW 156 FIGURE 37 PERKINELMER, INC.: COMPANY SNAPSHOT (2022) 157 12.1.6 QIAGEN 159 TABLE 116 QIAGEN: BUSINESS OVERVIEW 159 FIGURE 38 QIAGEN: COMPANY SNAPSHOT (2022) 160 12.1.7 SIEMENS HEALTHINEERS AG 162 TABLE 117 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 162 FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 163 12.1.8 DANAHER 164 TABLE 118 DANAHER: BUSINESS OVERVIEW 164 FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022) 165 12.1.9 BECTON, DICKINSON AND COMPANY 167 TABLE 119 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 167 FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 168 12.1.10 BIO-RAD LABORATORIES, INC. 169 TABLE 120 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 169 FIGURE 42 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2022) 170 12.2 OTHER PLAYERS 172 12.2.1 SEEGENE, INC. 172 12.2.2 MERIDIAN BIOSCIENCE 173 12.2.3 GENETIC SIGNATURES 174 12.2.4 ELITECHGROUP 174 12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 175 12.2.6 BINX HEALTH, INC. 175 12.2.7 VISBY MEDICAL, INC. 176 12.2.8 GENEPROOF A.S. 176 12.2.9 BIONEER CORPORATION 177 12.2.10 MICROBIOLOGICS 178 12.2.11 SANSURE BIOTECH, INC. 178 12.2.12 VIRCELL 179 12.2.13 OPERON 179 12.2.14 TIANLONG 180 12.2.15 GOFFIN MOLECULAR TECHNOLOGIES 180 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 13 APPENDIX 181 13.1 DISCUSSION GUIDE 181 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 184 13.3 CUSTOMIZATION OPTIONS 186 13.4 RELATED REPORTS 186 13.5 AUTHOR DETAILS 187
List of Tables/Graphs1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 25 1.3 STUDY SCOPE 25 1.3.1 MARKETS COVERED 25 1.3.2 GEOGRAPHIC SCOPE 26 1.3.3 YEARS CONSIDERED 26 1.4 CURRENCY CONSIDERED 27 1.5 LIMITATIONS 27 1.6 STAKEHOLDERS 27 1.7 SUMMARY OF CHANGES 28 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 2.2 RESEARCH APPROACH 29 FIGURE 1 CT/NG TESTING MARKET: RESEARCH DESIGN 29 2.2.1 SECONDARY DATA 30 2.2.1.1 Key data from secondary sources 30 2.2.2 PRIMARY DATA 31 2.2.2.1 Primary sources 32 2.2.2.2 Key data from primary sources 33 2.2.2.3 Key industry insights 34 2.2.2.4 Breakdown of primary interviews 34 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 34 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35 2.3 MARKET SIZE ESTIMATION 35 2.3.1 BOTTOM-UP APPROACH 36 2.3.1.1 Approach 1: Company revenue estimation approach 36 FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36 2.3.1.2 Approach 2: Presentations of companies and primary interviews 36 2.3.1.3 Growth forecast 37 2.3.1.4 CAGR projections 37 FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37 2.3.2 TOP-DOWN APPROACH 37 FIGURE 6 CT/NG TESTING MARKET: TOP-DOWN APPROACH 38 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39 FIGURE 7 DATA TRIANGULATION METHODOLOGY 39 2.5 MARKET SHARE ANALYSIS 40 2.6 STUDY ASSUMPTIONS 40 2.7 GROWTH RATE ASSUMPTIONS 40 2.8 RISK ASSESSMENT 41 2.8.1 CT/NG TESTING MARKET: RISK ASSESSMENT 41 2.9 RECESSION IMPACT 41 3 EXECUTIVE SUMMARY 44 FIGURE 8 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 44 FIGURE 9 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 (USD MILLION) 45 FIGURE 10 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 45 FIGURE 11 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46 FIGURE 12 CT/NG TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 46 4 PREMIUM INSIGHTS 48 4.1 CT/NG TESTING MARKET OVERVIEW 48 FIGURE 13 INCREASING PREVALENCE OF CT/NG INFECTIONS TO DRIVE MARKET 48 4.2 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 48 FIGURE 14 ASSAYS AND KITS SEGMENT TO DOMINATE CT/NG TESTING MARKET IN 2028 48 4.3 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 49 FIGURE 15 LABORATORY TESTING SEGMENT TO DOMINATE MARKET IN 2028 49 4.4 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 49 FIGURE 16 PCR SEGMENT TO DOMINATE CT/NG TESTING MARKET DURING STUDY PERIOD 49 4.5 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 50 FIGURE 17 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET IN 2028 50 4.6 CT/NG TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 50 FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN CT/NG TESTING MARKET DURING FORECAST PERIOD 50 5 MARKET OVERVIEW 51 5.1 INTRODUCTION 51 5.2 MARKET DYNAMICS 51 FIGURE 19 CT/NG TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 5.2.1 DRIVERS 52 5.2.1.1 Increasing prevalence of CT/NG infections 52 5.2.1.2 Increasing investments and initiatives in CT/NG 52 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies 53 5.2.2 RESTRAINTS 54 5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies 54 5.2.2.2 High cost of instruments and lack of budget for small laboratories and physicians’ offices 54 5.2.3 OPPORTUNITIES 55 5.2.3.1 Growth opportunities in emerging economies 55 5.2.4 CHALLENGES 55 5.2.4.1 Changing regulatory landscape in European Union and US 55 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians 56 5.3 PRICING ANALYSIS 56 TABLE 1 AVERAGE SELLING PRICE OF CT/NG TESTING PRODUCTS (2023) 56 5.4 PATENT ANALYSIS 57 FIGURE 20 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022) 57 5.4.1 LIST OF KEY PATENTS 58 5.5 VALUE CHAIN ANALYSIS 59 FIGURE 21 VALUE CHAIN ANALYSIS OF CT/NG TESTING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 60 5.6 SUPPLY CHAIN ANALYSIS 60 FIGURE 22 CT/NG TESTING MARKET: SUPPLY CHAIN ANALYSIS 61 5.7 ECOSYSTEM MARKET MAP 61 FIGURE 23 CT/NG TESTING MARKET: ECOSYSTEM MARKET MAP 62 5.7.1 CT/NG TESTING MARKET: ROLE IN ECOSYSTEM 62 5.8 PORTER’S FIVE FORCES ANALYSIS 63 TABLE 2 CT/NG TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 63 5.8.1 THREAT OF NEW ENTRANTS 63 5.8.2 THREAT OF SUBSTITUTES 63 5.8.3 BARGAINING POWER OF BUYERS 63 5.8.4 BARGAINING POWER OF SUPPLIERS 64 5.8.5 INTENSITY OF COMPETITIVE RIVALRY 64 5.9 REGULATORY ANALYSIS 64 TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64 TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65 5.9.1 NORTH AMERICA 66 5.9.1.1 US 66 5.9.1.2 Canada 66 5.9.2 EUROPE 66 TABLE 7 EUROPE: CLASSIFICATION OF DEVICES 66 5.9.3 ASIA PACIFIC 67 5.9.3.1 China 67 5.9.3.2 Japan 67 TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 67 5.9.3.3 India 68 5.9.4 LATIN AMERICA 68 5.9.4.1 Brazil 68 5.9.4.2 Mexico 68 5.9.5 MIDDLE EAST 68 5.9.6 AFRICA 69 5.10 TRADE ANALYSIS 69 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 69 TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 69 TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 69 5.11 PESTLE ANALYSIS 70 5.12 TECHNOLOGY ANALYSIS 71 5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 71 TABLE 11 CT/NG TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 71 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73 5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR CT/NG TESTING PRODUCT MANUFACTURERS 73 5.14.2 REVENUE SHIFT IN CT/NG TESTING MARKET 73 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 73 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 73 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CT/NG TESTING PRODUCTS 73 TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CT/NG TESTING PRODUCTS 74 5.15.2 BUYING CRITERIA 74 FIGURE 25 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS 74 TABLE 13 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS 74 6 CT/NG TESTING MARKET, BY PRODUCT 75 6.1 INTRODUCTION 76 TABLE 14 CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 76 6.2 ASSAYS AND KITS 76 6.2.1 RECURRENT REQUIREMENT AND PURCHASE OF ASSAYS AND KITS TO DRIVE GROWTH 76 TABLE 15 KEY ASSAYS AND KITS OFFERED BY MARKET PLAYERS 77 TABLE 16 CT/NG TESTING MARKET FOR ASSAYS AND KITS, BY REGION, 2021–2028 (USD MILLION) 77 6.3 INSTRUMENTS/ANALYZERS 77 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST GROWTH 77 TABLE 17 KEY INSTRUMENTS/ANALYZERS OFFERED BY MARKET PLAYERS 78 TABLE 18 CT/NG TESTING MARKET FOR INSTRUMENTS/ANALYZERS, BY REGION, 2021–2028 (USD MILLION) 78 7 CT/NG TESTING MARKET, BY TESTING TYPE 79 7.1 INTRODUCTION 80 TABLE 19 CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 80 7.2 LABORATORY TESTING 80 7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASING FOCUS ON EARLY DISEASE DETECTION TO DRIVE GROWTH 80 TABLE 20 CT/NG TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2021–2028 (USD MILLION) 81 7.3 POINT-OF-CARE TESTING 81 7.3.1 FASTER TURNAROUND TIME TO DRIVE GROWTH 81 TABLE 21 CT/NG TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2021–2028 (USD MILLION) 82 8 CT/NG TESTING MARKET, BY TECHNOLOGY 83 8.1 INTRODUCTION 84 TABLE 22 CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 84 8.2 PCR 84 8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS TO DRIVE GROWTH 84 TABLE 23 CT/NG TESTING MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION) 85 8.3 INAAT 85 8.3.1 COST-BENEFITS OF INAAT TO DRIVE GROWTH 85 TABLE 24 CT/NG TESTING MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION) 86 8.4 IMMUNODIAGNOSTICS 86 8.4.1 RISING PREVALENCE OF CT/NG AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE GROWTH 86 TABLE 25 CT/NG TESTING MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 87 8.5 OTHER TECHNOLOGIES 87 TABLE 26 CT/NG TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 88 9 CT/NG TESTING MARKET, BY END USER 89 9.1 INTRODUCTION 90 TABLE 27 CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 90 9.2 DIAGNOSTIC LABORATORIES 90 9.2.1 AVAILABILITY OF WIDE RANGE OF TEST PANELS FOR DISEASE TESTING TO SUPPORT GROWTH 90 TABLE 28 CT/NG TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 91 9.3 HOSPITALS AND CLINICS 91 9.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE GROWTH 91 TABLE 29 CT/NG TESTING MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION) 92 9.4 OTHER END USERS 92 TABLE 30 CT/NG TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 93 10 CT/NG TESTING MARKET, BY REGION 94 10.1 INTRODUCTION 95 TABLE 31 CT/NG TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 95 10.2 NORTH AMERICA 95 FIGURE 26 NORTH AMERICA: CT/NG TESTING MARKET SNAPSHOT 96 TABLE 32 NORTH AMERICA: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97 TABLE 33 NORTH AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 97 TABLE 34 NORTH AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 97 TABLE 35 NORTH AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 98 TABLE 36 NORTH AMERICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 98 10.2.1 RECESSION IMPACT: NORTH AMERICA 98 10.2.2 US 99 10.2.2.1 Growing prevalence of infectious diseases to drive market 99 TABLE 37 US: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99 TABLE 38 US: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 99 TABLE 39 US: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 100 TABLE 40 US: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 100 10.2.3 CANADA 100 10.2.3.1 Rising government initiatives to propel market growth in coming years 100 TABLE 41 CANADA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101 TABLE 42 CANADA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 101 TABLE 43 CANADA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 101 TABLE 44 CANADA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 102 10.3 EUROPE 102 TABLE 45 EUROPE: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103 TABLE 46 EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103 TABLE 47 EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 103 TABLE 48 EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 104 TABLE 49 EUROPE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 104 10.3.1 RECESSION IMPACT: EUROPE 104 10.3.2 GERMANY 105 10.3.2.1 Increasing healthcare expenditure to drive market growth 105 TABLE 50 GERMANY: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 105 TABLE 51 GERMANY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 105 TABLE 52 GERMANY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 106 TABLE 53 GERMANY: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 106 10.3.3 UK 106 10.3.3.1 Growing number of accredited diagnostic laboratories to propel market growth 106 TABLE 54 UK: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 107 TABLE 55 UK: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 107 TABLE 56 UK: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 107 TABLE 57 UK: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 108 10.3.4 FRANCE 108 10.3.4.1 Rising R&D expenditure in France to drive market growth 108 TABLE 58 FRANCE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108 TABLE 59 FRANCE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 109 TABLE 60 FRANCE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 109 TABLE 61 FRANCE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 109 10.3.5 ITALY 110 10.3.5.1 Adoption of advanced diagnostic technologies to favor growth 110 TABLE 62 ITALY: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110 TABLE 63 ITALY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 110 TABLE 64 ITALY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 111 TABLE 65 ITALY: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 111 10.3.6 SPAIN 111 10.3.6.1 Growing demand for diagnostic testing in Spain to favor market growth 111 TABLE 66 SPAIN: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 112 TABLE 67 SPAIN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 112 TABLE 68 SPAIN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 112 TABLE 69 SPAIN: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 113 10.3.7 REST OF EUROPE 113 TABLE 70 REST OF EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 113 TABLE 71 REST OF EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 114 TABLE 72 REST OF EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114 TABLE 73 REST OF EUROPE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 114 10.4 ASIA PACIFIC 115 FIGURE 27 ASIA PACIFIC: CT/NG TESTING MARKET SNAPSHOT 116 TABLE 74 ASIA PACIFIC: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117 TABLE 75 ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 117 TABLE 76 ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 117 TABLE 77 ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118 TABLE 78 ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 118 10.4.1 RECESSION IMPACT: ASIA PACIFIC 118 10.4.2 CHINA 119 10.4.2.1 Growing public access to modern healthcare to drive market growth 119 TABLE 79 CHINA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119 TABLE 80 CHINA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 120 TABLE 81 CHINA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120 TABLE 82 CHINA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 120 10.4.3 JAPAN 121 10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan 121 TABLE 83 JAPAN: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121 TABLE 84 JAPAN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 122 TABLE 85 JAPAN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122 TABLE 86 JAPAN: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 122 10.4.4 INDIA 123 10.4.4.1 Increasing private and public investments in country’s healthcare system to drive market growth 123 TABLE 87 INDIA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123 TABLE 88 INDIA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 124 TABLE 89 INDIA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124 TABLE 90 INDIA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 124 10.4.5 REST OF ASIA PACIFIC 125 TABLE 91 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125 TABLE 92 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 125 TABLE 93 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126 TABLE 94 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 126 10.5 LATIN AMERICA 126 10.5.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE GROWTH OF CT/NG TESTING MARKET IN LATIN AMERICA 126 TABLE 95 LATIN AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127 TABLE 96 LATIN AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 127 TABLE 97 LATIN AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128 TABLE 98 LATIN AMERICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 128 10.5.2 RECESSION IMPACT: LATIN AMERICA 128 10.6 MIDDLE EAST & AFRICA 129 10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH 129 TABLE 99 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129 TABLE 100 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 130 TABLE 101 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130 TABLE 102 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 130 10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA 131 11 COMPETITIVE LANDSCAPE 132 11.1 OVERVIEW 132 11.2 STRATEGIES OF KEY PLAYERS 132 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CT/NG TESTING MARKET 132 TABLE 103 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CT/NG TESTING PRODUCTS MANUFACTURING COMPANIES 132 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 134 FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CT/NG TESTING MARKET 134 11.4 MARKET SHARE ANALYSIS 134 11.4.1 CT/NG TESTING MARKET 134 FIGURE 29 CT/NG TESTING MARKET SHARE, BY KEY PLAYER (2022) 135 TABLE 104 CT/NG TESTING MARKET: DEGREE OF COMPETITION 135 11.5 COMPANY EVALUATION MATRIX, 2022 136 11.5.1 STARS 136 11.5.2 EMERGING LEADERS 136 11.5.3 PERVASIVE PLAYERS 137 11.5.4 PARTICIPANTS 137 FIGURE 30 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX, 2022 137 11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 138 11.6.1 PROGRESSIVE COMPANIES 138 11.6.2 STARTING BLOCKS 138 11.6.3 RESPONSIVE COMPANIES 138 11.6.4 DYNAMIC COMPANIES 138 FIGURE 31 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 139 11.7 COMPETITIVE BENCHMARKING 140 11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 140 FIGURE 32 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS 140 TABLE 105 CT/NG TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 140 TABLE 106 PRODUCT FOOTPRINT OF COMPANIES 141 TABLE 107 REGIONAL FOOTPRINT OF COMPANIES 141 TABLE 108 CT/NG TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES 141 11.8 COMPETITIVE SCENARIO 142 11.8.1 PRODUCT LAUNCHES 142 TABLE 109 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 142 11.8.2 DEALS 142 TABLE 110 KEY DEALS 142 12 COMPANY PROFILES 143 12.1 KEY PLAYERS 143 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 12.1.1 F. HOFFMANN-LA ROCHE LTD 143 TABLE 111 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 143 FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 144 12.1.2 HOLOGIC, INC. 147 TABLE 112 HOLOGIC, INC.: BUSINESS OVERVIEW 147 FIGURE 34 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 148 12.1.3 THERMO FISHER SCIENTIFIC, INC. 150 TABLE 113 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 150 FIGURE 35 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 151 12.1.4 ABBOTT LABORATORIES 153 TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW 153 FIGURE 36 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 154 12.1.5 PERKINELMER, INC. 156 TABLE 115 PERKINELMER, INC.: BUSINESS OVERVIEW 156 FIGURE 37 PERKINELMER, INC.: COMPANY SNAPSHOT (2022) 157 12.1.6 QIAGEN 159 TABLE 116 QIAGEN: BUSINESS OVERVIEW 159 FIGURE 38 QIAGEN: COMPANY SNAPSHOT (2022) 160 12.1.7 SIEMENS HEALTHINEERS AG 162 TABLE 117 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 162 FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 163 12.1.8 DANAHER 164 TABLE 118 DANAHER: BUSINESS OVERVIEW 164 FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022) 165 12.1.9 BECTON, DICKINSON AND COMPANY 167 TABLE 119 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 167 FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 168 12.1.10 BIO-RAD LABORATORIES, INC. 169 TABLE 120 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 169 FIGURE 42 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2022) 170 12.2 OTHER PLAYERS 172 12.2.1 SEEGENE, INC. 172 12.2.2 MERIDIAN BIOSCIENCE 173 12.2.3 GENETIC SIGNATURES 174 12.2.4 ELITECHGROUP 174 12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 175 12.2.6 BINX HEALTH, INC. 175 12.2.7 VISBY MEDICAL, INC. 176 12.2.8 GENEPROOF A.S. 176 12.2.9 BIONEER CORPORATION 177 12.2.10 MICROBIOLOGICS 178 12.2.11 SANSURE BIOTECH, INC. 178 12.2.12 VIRCELL 179 12.2.13 OPERON 179 12.2.14 TIANLONG 180 12.2.15 GOFFIN MOLECULAR TECHNOLOGIES 180 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 13 APPENDIX 181 13.1 DISCUSSION GUIDE 181 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 184 13.3 CUSTOMIZATION OPTIONS 186 13.4 RELATED REPORTS 186 13.5 AUTHOR DETAILS 187
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
MarketsandMarkets社のMedical Devices分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |